Published Date:2021-04-07 Original Link:https://www.onenessbio.com/en/news_detail36_3.htm No 1 Date of announcement 2021/04/07 Time of announcement 19:21:18 Subject Oneness has submitted the phase 2 clinical trial application for FB704A, a fully-human anti-IL6 antibody new drug, in severe asthma to TFDA via fast track.      To which item it meets paragraph 10 Date of events 2021/04/07 Statement 1.Product:FB704A...Read More